BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Emraclidine readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Emraclidine\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07219030-705@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Emraclidine: Phase 1 readout est. (NCT07219030)
DESCRIPTION:Emraclidine\, phase 1.\nStudy: A Study to Assess the Adverse Ev
 ents and How Oral Emraclidine Moves Through the Body of Healthy Elderly Ad
 ult Participants\nEstimated primary completion: December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/emraclidine#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07219030
URL:https://assetmemo.bio/drug/emraclidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07145918-705@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Emraclidine: Phase 2 readout est. (NCT07145918)
DESCRIPTION:Emraclidine\, phase 2\, Schizophrenia.\nStudy: A Study to Asses
 s Adverse Events\, Change in Disease Activity\, and How Oral Emraclidine M
 oves Through the Body in Adult Participants With Schizophrenia\nEstimated 
 primary completion: February 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/emraclidine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07145918
URL:https://assetmemo.bio/drug/emraclidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
